Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an asian tertiary phase i oncology unit

HIGHLIGHTS

• What: For the purposes of this analysis, the variants of uncertain significance were excluded. The authors report a retrospective analysis of MBC patients enrolled in the Integrated Molecular Analysis of Cancer (IMAC) study from April 28, 2014, to January 31, 2022. In this retrospective study of a cohort of MBC patients from a tertiary oncology centre in Asia, the authors report a higher PFS for patients receiving matched versus unmatched treatment, a finding consistent with prior publications . The authors report a subgroup of patients who received ICI treatment for MBC (19/105 patients) of whom five had . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.